Statement of changes in beneficial ownership of securities – 6/2/2022

Post navigation

← Previous Filings

Next Filings →

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name*

Email*

Website

Save my name, email, and website in this browser for the next time I comment.

#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

Cannabinoids in Development
INM-755 for Epidermolysis Bullosa
INM-088 for Glaucoma
Neurodegenerative Disease
Novel Cannabinoid Analogs

MANUFACTURING

Cannabinoid Manufacturing Expertise
IntegraSyn™ Cannabinoid Manufacturing
BayMedica Cannabinoid Biosynthesis
Rare Cannabinoid Ingredients

Investor

News
Events
Stock Information
Corporate Governance
Financials & AGM
Filings
Presentations
Media

CORPORATE

Management
Board of Directors
Scientific Advisory Board
Partners and Collaborators
Careers
Contact

Learn

What is Cannabinol (CBN)?
What is Epidermolysis Bullosa (EB)?
What is Glaucoma?
Cannabinoid Manufacturing Economics 101
GMP Manufacturing Standards by Product Type
Cannabinoids for Glaucoma
Cannabinoid Science
Articles and Videos

Privacy Policy
Terms of Use
Legal Disclaimer

Find Us On:

Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*

First name* Last name*

Email*

Consent

By providing your e-mail address, you consent to receive news, press releases, quarterly and annual reports, presentations and other information from InMed Pharmaceuticals Inc. You can unsubscribe at any time.